Start here if you're new
what it is
Alpha Cognition is trying to turn one newly approved Alzheimer’s pill into a commercial drug company.
how it gets paid
FY2025 GAAP revenue ~$10.2M—~$6.8M ZUNVEYL net product sales + ~$3.4M licensing (first full commercial year; FY2024 product revenue was $0).
what just happened
Q4’25 ZUNVEYL net product revenue ~$2.5M; full-year net loss ~$20.7M (basic LPS ~$(1.17)). Cash ~$66M YE 2025—company cites ~two-year runway at forecasted spend.
At a glance
n/a balance sheet
~$(1.17) FY2025 basic LPS (GAAP)
~$109M market cap @ ~$5
small cap
NASDAQ
What they do
Alpha Cognition is trying to turn one newly approved Alzheimer’s pill into a commercial drug company.
The moat is small and mostly regulatory. On July 26, 2024, the FDA approved ZUNVEYL, which gave a 52-employee company something rare: a medicine your doctor can actually prescribe. FDA approval (legal permission to sell a drug) → real prescriptions → a shot at revenue, and that matters more than pipeline slides.
How they make money
~$10.2M
FY2025 total revenue · first full year of ZUNVEYL sales + licensing
ZUNVEYL net product revenue (FY2025)
~$6.8M
vs. $0 FY2024
Licensing & other (FY2025)
~$3.4M
FY2025
FY2025: Business Wire Mar 26, 2026 (unaudited; 10-K to follow).
The products that matter
alzheimer's disease treatment
ZUNVEYL
~$6.8M FY2025 product · ~$10.2M total rev
Entire commercial story is ZUNVEYL + small licensing. FY2025 actuals beat the kind of “cut forecast” narrative that showed up mid-year—still early LTC adoption; 2026 is execution.
only revenue source
pre-revenue drug development
Pipeline (mTBI, ALS)
$0 revenue today
the pipeline may matter later, but right now it contributes no revenue. Your cash has to fund both ZUNVEYL commercialization and the rest of the development work.
option value, not cash flow
Key numbers
~$2.5M
Q4’25 ZUNVEYL sales
Net product revenue line in Q4’25 release—total quarterly revenue also includes licensing (order-of-magnitude ~$3M).
$(1.17)
FY2025 basic LPS
GAAP net loss ~$20.7M on ~17.7M weighted basic shares (per FY2025 tables in release).
52
employees
This is a very small team trying to commercialize an Alzheimer’s drug, which keeps both upside and execution risk high.
~$66M
cash YE 2025
Pro forma includes Oct 2025 raise; company guides ~two-year runway at forecasted operating levels.
Financial health
n/a
strength
- balance sheet grade n/a
n/a — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for ACOG right now.
source: institutional data · return history unavailable
What just happened
FY2025
FY2025 revenue ~$10.2M · net loss ~$20.7M · basic LPS ~$(1.17). Q4’25 ZUNVEYL net product ~$2.5M.
This is the first audited-adjacent full year with real product revenue (FY2024 was $0 product sales in the same table). Operating loss ~$22.7M; SG&A stepped up to ~$29.1M as commercial infrastructure scaled.
~$10.2M
FY2025 revenue
$(1.17)
FY basic LPS
~$66M
cash YE ’25
the number that mattered
Repeat utilization in long-term care + payer pull-through (now two of four major LTC PBMs contracted) decide whether ~$10M FY2025 becomes a real ramp in 2026.
source: Business Wire Mar 26, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is ZUNVEYL launch failure after the forecast cut.
med
single-product concentration
100% of reported revenue comes from ZUNVEYL. There is no second commercial asset to offset a weak launch.
impact: if ZUNVEYL misses, it exposes essentially all ~$10M FY2025 revenue at once.
med
forecast credibility
Mid-2025, management cut product revenue guidance sharply vs. early launch targets—FY2025 still reached ~$10.2M total revenue, but credibility on forward forecasts matters.
impact: the path to 2027 operating profitability still depends on a steep commercial ramp from a small base.
med
commercial adoption pace
the company wants roughly 2,000 prescribers. FY2025 net product revenue ~$6.8M says adoption is still early, and slow uptake can turn a launch story into a financing story.
impact: with a -262% net margin, delayed prescriber growth keeps losses elevated for longer.
a weaker launch does not just trim upside here — it pressures 100% of revenue, stretches the path to 2027 profitability, and leaves the pipeline carrying costs without commercial support.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
Q4 and full-year 2025 results
March 26, 2026 is the next reality check. You want ZUNVEYL sales against the reduced $5.7M forecast and any change to the 2027 profitability timeline.
adoption
prescriber count versus the 2,000 goal
This is the cleanest operating metric on the page. More doctors writing the drug is how ~$6.8M FY2025 product revenue becomes something bigger.
sales
whether revenue gets back above the cut plan
The company already reset expectations from $11.7M to $5.7M. First step before dreaming about tenfold growth: prove the revised number was conservative, not optimistic.
thesis risk
any slip in the 2027 profitability target
If that date moves out while sales remain small, the story shifts from commercialization upside to balance-sheet endurance.
Analyst rankings
coverage
1 analyst
in human-speak, analyst coverage is barely coverage. one $18 target can be useful, but it is not consensus.
target gap
$18 vs. $5.01
the spread looks enormous because it is. It also reflects how fragile small-cap biotech target data can be when only one voice is in the room.
source: institutional data
Institutional activity
institutional ownership data for ACOG is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$5
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive